<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02097485</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-008</org_study_id>
    <nct_id>NCT02097485</nct_id>
  </id_info>
  <brief_title>Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation</brief_title>
  <official_title>A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate ovicidal efficacy of a single application of&#xD;
      abametapir lotion 0.74% w/w intended for the treatment of head lice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, randomised, vehicle-controlled, parallel group study in males and&#xD;
      females, aged three years and older with active head lice infestation. The study was designed&#xD;
      to assess the ovicidal efficacy of a single application of abametapir lotion 0.74% w/w&#xD;
      compared to a vehicle control, when applied to the scalp and hair for 10 minutes at the study&#xD;
      site. This study used an ex vivo method of assessment for ovicidal efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment</measure>
    <time_frame>14 days</time_frame>
    <description>Percentage of hatched eggs pre treatment relative to percentage of hatched eggs post treatment for the abametapir and vehicle treated eggs following 14 day incubation. The difference between post treatment percent hatching and pre-treatment percent hatching was calculated i.e. post-treatment minus pre-treatment hatching percent.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Head Lice Infestation</condition>
  <arm_group>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topically administered to hair and scalp for 10 minutes application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered to scalp and hair for 10 minutes application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abametapir Lotion 0.74% w/w</intervention_name>
    <description>200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
    <arm_group_label>Abametapir Lotion 0.74% w/w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <description>control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
    <arm_group_label>Vehicle Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female based on medical history&#xD;
&#xD;
          2. Six months of age or older.&#xD;
&#xD;
          3. Has an active head lice infestation with a minimum of 3 live head lice and at least 10&#xD;
             undamaged and unhatched head lice eggs in their hair.&#xD;
&#xD;
          4. Agrees to an examination for head lice and compliance with the study procedures.&#xD;
&#xD;
          5. All adult subjects must sign a written voluntary informed consent. For minors, the&#xD;
             parent/ legal guardian agrees to the subject participating in the study as determined&#xD;
             by the signing of an assent of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has scalp disease or a history of allergies or prior reactions to any head lice&#xD;
             products.&#xD;
&#xD;
          2. Has a condition that, in the opinion of the Investigator, may interfere with the&#xD;
             study.&#xD;
&#xD;
          3. Is receiving systemic or topical medication, which in the opinion of the Investigator,&#xD;
             may compromise the integrity of the safety and/or efficacy assessments.&#xD;
&#xD;
          4. Had treatment (over-the-counter (OTC) or home remedy medication) for head lice within&#xD;
             14 days prior to Day 0.&#xD;
&#xD;
          5. Has received an investigational agent within 30 days prior to Day 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Arnold, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Head Lice Treatment Centre, Ringwood East, Victoria, Australia, 3135</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Head Lice Treatment Centre</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2014</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <disposition_first_submitted>March 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2016</disposition_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Mite Infestations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Topically administered to hair and scalp for 10 minutes application.&#xD;
Abametapir Lotion 0.74% w/w: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Lotion</title>
          <description>Administered to scalp and hair for 10 minutes application.&#xD;
Vehicle Lotion: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Population included subjects who were randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Topically administered to hair and scalp for 10 minutes application.&#xD;
Abametapir Lotion 0.74% w/w: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Lotion</title>
          <description>Administered to scalp and hair for 10 minutes application.&#xD;
Vehicle Lotion: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.7" spread="3.43"/>
                    <measurement group_id="B2" value="8.3" spread="2.95"/>
                    <measurement group_id="B3" value="8.5" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment</title>
        <description>Percentage of hatched eggs pre treatment relative to percentage of hatched eggs post treatment for the abametapir and vehicle treated eggs following 14 day incubation. The difference between post treatment percent hatching and pre-treatment percent hatching was calculated i.e. post-treatment minus pre-treatment hatching percent.</description>
        <time_frame>14 days</time_frame>
        <population>Full Analysis Set (FAS) included all randomized subjects who received any amount of study treatment and had at least 1 viable pre-treatment egg and 1 viable post-treatment egg evaluable for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Abametapir Lotion 0.74% w/w</title>
            <description>Topically administered to hair and scalp for 10 minutes application.&#xD;
Abametapir Lotion 0.74% w/w: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Lotion</title>
            <description>Administered to scalp and hair for 10 minutes application.&#xD;
Vehicle Lotion: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment</title>
          <description>Percentage of hatched eggs pre treatment relative to percentage of hatched eggs post treatment for the abametapir and vehicle treated eggs following 14 day incubation. The difference between post treatment percent hatching and pre-treatment percent hatching was calculated i.e. post-treatment minus pre-treatment hatching percent.</description>
          <population>Full Analysis Set (FAS) included all randomized subjects who received any amount of study treatment and had at least 1 viable pre-treatment egg and 1 viable post-treatment egg evaluable for analysis.</population>
          <units>Percent hatched eggs post versus pre Rx</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.9" lower_limit="-99.4" upper_limit="-86.5"/>
                    <measurement group_id="O2" value="-42.3" lower_limit="-54.4" upper_limit="-30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the start of treatment on Day 0 through the Day 7 follow up visit (Approximately 8 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Abametapir Lotion 0.74% w/w</title>
          <description>Topically administered to hair and scalp for 10 minutes application.&#xD;
Abametapir Lotion 0.74% w/w: 200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Lotion</title>
          <description>Administered to scalp and hair for 10 minutes application.&#xD;
Vehicle Lotion: control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Srinivas Sidgiddi</name_or_title>
      <organization>Dr. Reddy's Laboratories Inc.</organization>
      <phone>9084585362</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

